Expert Interview
Digging into the topline results from Study 403 evaluating Intra-Cellular's CAPLYTA (lumateperone) in patients with MDD or bipolar depression
Ticker(s): ITCIInstitution: Private Practice & UPenn
- Professor of Psychiatry at the Perelman School of Medicine of the University of Pennsylvania.
- Leading figure in the pharmacotherapy of mood disorders. Research focuses on the assessment and treatment of mood disorders, including studies of the differential therapeutics of both depression and bipolar affective disorder.
- Has authored or co-authored more than 500 scientific articles and book chapters, as well as 15 books.
How would Caplyta differ from other treatments for MDD?
Added By: max_adminHow many patients do you treat for major depressive disorder
and for bipolar depression?
How would you compare these results with lurasidone?
Now, this trial was an earlier stage trial, a Phase II, and they're going to nowadvance into Phase III program. Do you think that this could serve as one of thepivotal trials, and they'd run only a single Phase III, or do you think they have torun two Phase III trials after that?
Added By: slingshot_insightsDo you think that these results would increase the prescribing of CAPLYTA for bipolar disorder?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
